These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

65 related articles for article (PubMed ID: 8843968)

  • 1. Changes of Ki67 index of various tumors during radiation therapy.
    Kovarík J; Skry GD; Mikel J; Svoboda VH
    Neoplasma; 1996; 43(2):89-92. PubMed ID: 8843968
    [TBL] [Abstract][Full Text] [Related]  

  • 2. High growth fraction at 9 grays of radiotherapy is associated with a good prognosis for patients with cervical squamous cell carcinoma.
    Oka K; Suzuki Y; Nakano T
    Cancer; 2000 Oct; 89(7):1526-31. PubMed ID: 11013367
    [TBL] [Abstract][Full Text] [Related]  

  • 3. p53 protein overexpression is associated with increased cell proliferation in patients with locally recurrent prostate carcinoma after radiation therapy.
    Cheng L; Sebo TJ; Cheville JC; Pisansky TM; Slezak J; Bergstralh EJ; Pacelli A; Neumann RM; Zincke H; Bostwick DG
    Cancer; 1999 Mar; 85(6):1293-9. PubMed ID: 10189134
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Prognostic value of Ki67 expression after short-term presurgical endocrine therapy for primary breast cancer.
    Dowsett M; Smith IE; Ebbs SR; Dixon JM; Skene A; A'Hern R; Salter J; Detre S; Hills M; Walsh G;
    J Natl Cancer Inst; 2007 Jan; 99(2):167-70. PubMed ID: 17228000
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Malignant ileocaecal serotonin-producing carcinoid tumours: the presence of a solid growth pattern and/or Ki67 index above 1% identifies patients with a poorer prognosis.
    Cunningham JL; Grimelius L; Sundin A; Agarwal S; Janson ET
    Acta Oncol; 2007; 46(6):747-56. PubMed ID: 17653896
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Pathologic features, proliferative activity, and cyclin D1 expression in Hurthle cell neoplasms of the thyroid.
    Erickson LA; Jin L; Goellner JR; Lohse C; Pankratz VS; Zukerberg LR; Thompson GB; van Heerden JA; Grant CS; Lloyd RV
    Mod Pathol; 2000 Feb; 13(2):186-92. PubMed ID: 10697277
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Molecular markers of outcome after radiotherapy in patients with prostate carcinoma: Ki-67, bcl-2, bax, and bcl-x.
    Pollack A; Cowen D; Troncoso P; Zagars GK; von Eschenbach AC; Meistrich ML; McDonnell T
    Cancer; 2003 Apr; 97(7):1630-8. PubMed ID: 12655519
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Comparison of HER-2 status determined by fluorescence in situ hybridization in primary and metastatic breast carcinoma.
    Gong Y; Booser DJ; Sneige N
    Cancer; 2005 May; 103(9):1763-9. PubMed ID: 15786420
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Ki-67 staining is an independent correlate of biochemical failure in prostate cancer treated with radiotherapy.
    Cowen D; Troncoso P; Khoo VS; Zagars GK; von Eschenbach AC; Meistrich ML; Pollack A
    Clin Cancer Res; 2002 May; 8(5):1148-54. PubMed ID: 12006531
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Ki-67 expression in cytologic scrapes from oral squamous cell carcinoma before and after 24 gray radiotherapy--a study on 43 patients.
    Sharma P; Kumar N; Bahadur AK; Mandal AK
    Med Oral Patol Oral Cir Bucal; 2005 Apr; 10 Suppl 1():E15-7. PubMed ID: 15800463
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Nuclear DNA content, an adjunct to p53 and Ki-67 as a marker of resistance to radiation therapy in oral cavity and pharyngeal squamous cell carcinoma.
    Raybaud H; Fortin A; Bairati I; Morency R; Monteil RA; Têtu B
    Int J Oral Maxillofac Surg; 2000 Feb; 29(1):36-41. PubMed ID: 10691142
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Potential indicators of radiosensitivity in squamous cell carcinoma of the head and neck.
    Sheridan MT; O'Dwyer T; Seymour CB; Mothersill CE
    Radiat Oncol Investig; 1997; 5(4):180-6. PubMed ID: 9327497
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Flow cytometry vs. Ki67 labelling index in breast cancer: a prospective evaluation of 181 cases.
    Martínez-Arribas F; Núñez MJ; Piqueras V; Lucas AR; Sánchez J; Tejerina A; Schneider J
    Anticancer Res; 2002; 22(1A):295-8. PubMed ID: 12017306
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Toxicity and outcome results of RTOG 9311: a phase I-II dose-escalation study using three-dimensional conformal radiotherapy in patients with inoperable non-small-cell lung carcinoma.
    Bradley J; Graham MV; Winter K; Purdy JA; Komaki R; Roa WH; Ryu JK; Bosch W; Emami B
    Int J Radiat Oncol Biol Phys; 2005 Feb; 61(2):318-28. PubMed ID: 15667949
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Biomarker changes during neoadjuvant anastrozole, tamoxifen, or the combination: influence of hormonal status and HER-2 in breast cancer--a study from the IMPACT trialists.
    Dowsett M; Ebbs SR; Dixon JM; Skene A; Griffith C; Boeddinghaus I; Salter J; Detre S; Hills M; Ashley S; Francis S; Walsh G; Smith IE
    J Clin Oncol; 2005 Apr; 23(11):2477-92. PubMed ID: 15767642
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Evaluation of Ki-67 proliferation and apoptotic index before, during and after neoadjuvant chemotherapy for primary breast cancer.
    Burcombe R; Wilson GD; Dowsett M; Khan I; Richman PI; Daley F; Detre S; Makris A
    Breast Cancer Res; 2006; 8(3):R31. PubMed ID: 16790076
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Apoptosis and proliferation as predictors of chemotherapy response in patients with breast carcinoma.
    Chang J; Ormerod M; Powles TJ; Allred DC; Ashley SE; Dowsett M
    Cancer; 2000 Dec; 89(11):2145-52. PubMed ID: 11147583
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Differences in Ki67 and c-erbB2 expression between screen-detected and true interval breast cancers.
    Crosier M; Scott D; Wilson RG; Griffiths CD; May FE; Westley BR
    Clin Cancer Res; 1999 Oct; 5(10):2682-8. PubMed ID: 10537329
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Measurement of proliferation marker Ki67 in breast tumour FNAs using laser scanning cytometry in comparison to conventional immunocytochemistry.
    Zabaglo L; Ormerod MG; Dowsett M
    Cytometry B Clin Cytom; 2003 Nov; 56(1):55-61. PubMed ID: 14582137
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Clinical, histopathologic, and immunohistochemical features of microglandular adenosis and transition into in situ and invasive carcinoma.
    Khalifeh IM; Albarracin C; Diaz LK; Symmans FW; Edgerton ME; Hwang RF; Sneige N
    Am J Surg Pathol; 2008 Apr; 32(4):544-52. PubMed ID: 18300793
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 4.